Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Replikins Blocker-Vaccine
- Development stage
- Preclinical
- Lead developer
- Replikins
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Upper Respiratory, Oral, Gastrointestinal
01
Overview
Replikins Blocker-Vaccine (also known as Synthetic Replikins Blocker-Vaccine) is a synthetic peptide-based vaccine platform developed by Replikins, Ltd. The vaccine candidates are composed of synthetic genomic-based peptides designed to match conserved "Replikin" sequences found in viral genomes, which are statistically associated with rapid viral replication. By targeting these specific sequences, the vaccine is intended to block viral replication and induce protective immunity. The manufacturing process utilizes solid-phase peptide synthesis, allowing for rapid production (approximately seven days) and a freeze-dried final product that does not require refrigeration. Various formulations have been developed, including a trivalent candidate for Zika, Dengue, and Japanese Encephalitis, as well as candidates for Influenza (H5N1, H1N1) and SARS.
- Other names
- Synthetic Replikins Blocker-VaccineReplikins Vaccine-Blocker
Beyond the preview
Go deeper on Replikins Blocker-Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Replikins Blocker-Vaccine.